Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of SpringWorks Therapeutics Inc (NASDAQ: SWTX) was $37.93 for the day, up 9.75% from the previous closing price of $34.56. In other words, the price has increased by $9.75 from its previous closing price. On the day, 1.1 million shares were traded. SWTX stock price reached its highest trading level at $37.96 during the session, while it also had its lowest trading level at $34.29.
Ratios:
Our analysis of SWTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.02 and its Current Ratio is at 6.16. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on February 05, 2024, initiated with a Buy rating and assigned the stock a target price of $75.
On December 01, 2022, BofA Securities started tracking the stock assigning a Buy rating and target price of $45.
H.C. Wainwright reiterated its Buy rating for the stock on January 19, 2021, while the target price for the stock was revised from $87 to $101.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 03 ’24 when Islam Saqib sold 49,000 shares for $40.57 per share. The transaction valued at 1,988,033 led to the insider holds 1,063,368 shares of the business.
Edris Badreddin sold 20,000 shares of SWTX for $812,954 on Sep 03 ’24. The Chief Operating Officer now owns 229,600 shares after completing the transaction at $40.65 per share. On Sep 03 ’24, another insider, Badreddin Edris, who serves as the Officer of the company, bought 50,000 shares for $41.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SWTX now has a Market Capitalization of 2821476096 and an Enterprise Value of 2200351744. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.82 while its Price-to-Book (P/B) ratio in mrq is 5.29. Its current Enterprise Value per Revenue stands at 16.24 whereas that against EBITDA is -7.529.
Stock Price History:
Over the past 52 weeks, SWTX has reached a high of $53.92, while it has fallen to a 52-week low of $20.19. The 50-Day Moving Average of the stock is 16.38%, while the 200-Day Moving Average is calculated to be -5.33%.
Shares Statistics:
SWTX traded an average of 1.04M shares per day over the past three months and 1947350 shares per day over the past ten days. A total of 73.49M shares are outstanding, with a floating share count of 65.79M. Insiders hold about 11.56% of the company’s shares, while institutions hold 102.01% stake in the company. Shares short for SWTX as of 1730332800 were 11625524 with a Short Ratio of 11.17, compared to 1727654400 on 12179183. Therefore, it implies a Short% of Shares Outstanding of 11625524 and a Short% of Float of 18.94.
Earnings Estimates
SpringWorks Therapeutics Inc (SWTX) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.44 and low estimates of -$0.88.
Analysts are recommending an EPS of between -$3.03 and -$3.22 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$1.71, with 5.0 analysts recommending between -$0.65 and -$3.32.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $66.8M to a low estimate of $58.41M. As of the current estimate, SpringWorks Therapeutics Inc’s year-ago sales were $5.45MFor the next quarter, 5 analysts are estimating revenue of $71.8M. There is a high estimate of $77.6M for the next quarter, whereas the lowest estimate is $66.6M.
A total of 7 analysts have provided revenue estimates for SWTX’s current fiscal year. The highest revenue estimate was $196.8M, while the lowest revenue estimate was $187.1M, resulting in an average revenue estimate of $192.24M. In the same quarter a year ago, actual revenue was $5.45MBased on 7 analysts’ estimates, the company’s revenue will be $374.2M in the next fiscal year. The high estimate is $420.37M and the low estimate is $310.5M.
